SOLID TUMORS

This early-stage study tests a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in 50 adults with solid tumors. The goal is to see if the vaccine is safe and triggers an immune response against the cancer. Participants must have completed or…

This early-phase study tests a new drug called KIVU-305 in 76 adults with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goal is to find the safest dose and che…

This study tests an experimental drug, BMS-986504, in people with advanced solid tumors that have a specific gene deletion called MTAP. The drug is given alone or with other cancer treatments. The goal is to see if the drug can shrink tumors and to check for side effects. About 2…

This early-phase study tests a new combination of two drugs, risvutatug rezetecan and ivonescimab, in about 184 adults with advanced solid tumors that have spread. The main goals are to find safe doses, understand side effects, and see if the combination can shrink tumors. This i…

This early-stage study tests a new drug called HEMAY5087 in about 24 adults with advanced solid tumors that have not responded to standard treatments or have no available therapies. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors…

This study tests a new drug called RC288 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 326 adults aged 18 to 75 with good overall health will take part.

This early-phase study tests a new treatment using specially engineered natural killer (NK) cells boosted with IL-15 to fight advanced solid tumors that have not responded to standard therapies. About 12 adults aged 18-70 with metastatic or recurrent cancers like breast, liver, o…

This early-stage study tests a new drug, ATB-320, in 24 adults with solid tumors that have spread or are getting worse despite standard treatments. The main goal is to find a safe dose and check for side effects. Participants must provide tumor samples and have tumors that can be…

This early-phase study tests a new type of immunotherapy called CD70 CAR T cells in people with lymphoma, myeloma, and certain solid tumors (like kidney cancer and sarcomas) that have returned or not responded to standard treatments. The treatment involves taking a patient's own …

This early-phase study tests a drug called zanidatamab in 10 adults with advanced HER2-positive solid tumors (like endometrial, bladder, or pancreatic cancer) that have worsened after at least one prior treatment. Participants receive the drug by IV every two weeks. The main goal…

This study tests a new approach for people with solid tumors (like breast cancer) that have spread to the brain. The drugs used are called theranostic agents—they can both find cancer cells and deliver radiation to kill them. The trial will first check if the drug reaches the bra…

This early-phase study tests a personalized cell therapy for people with extensive-stage small cell lung cancer or similar neuroendocrine cancers that came back after standard treatment. Researchers take a patient's own immune cells, modify them to recognize a protein called B7-H…

This early-phase study tests a new drug (BI 1831169) combined with an existing immunotherapy (anti-PD1 antibody) in Japanese adults with advanced solid tumors that have spread or no longer respond to standard treatments. The main goal is to find the highest safe dose of the combi…

This study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…

This study tests whether combining lenvatinib (a targeted therapy) with a PD-1 inhibitor (immunotherapy) can shrink or stop advanced solid tumors that have a specific genetic change called 11q13 amplification. About 60 adults with various cancers (like esophageal, head and neck, …

This study looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to stop antibiotics early or continue standard treatment. The goal is to see if early stoppi…

This early-phase study tests a new drug called QLS5316 in about 300 adults with advanced solid tumors (such as colorectal, stomach, head and neck, or lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, a…

This study tests a drug called romiplostim N01 in 60 adults with solid tumors who have low platelets after radiation combined with other cancer treatments. The goal is to see if the drug can safely raise platelet counts and reduce the need for transfusions. It is a phase 2 trial,…

This early-phase trial tests an experimental drug called FXB0871 in about 138 adults with advanced solid tumors, including non-small cell lung cancer and liver cancer, that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and se…

This study will test a new imaging agent called 68Ga-B6FA-01, which targets two different markers on cancer cells and their surroundings. The goal is to see if this probe can improve PET/CT scans for diagnosing and staging solid tumors. About 100 adults with newly diagnosed or re…

This early study will test a new type of PET scan that uses two targets (FAPI and PSMA) at once to find and stage solid tumors like prostate, liver, ovarian, and endometrial cancers. About 20 adults with suspected or confirmed tumors will get this new scan, and doctors will compa…